ABCL - AbCellera Biologics Inc.
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 6.91 |
| Open | 6.97 |
| Bid | 7.30 x 1100 |
| Ask | 7.31 x 1000 |
| Day's Range | 6.94 - 7.40 |
| 52 Week Range | 5.53 - 14.97 |
| Volume | |
| Avg. Volume | 2,092,585 |
| Market Cap | 2.105B |
| Beta (5Y Monthly) | -0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.18 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.67 |
Fair Value
Related Research
Business WireAbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
VANCOUVER, British Columbia, May 29, 2023--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
Simply Wall St.Strong week for AbCellera Biologics (NASDAQ:ABCL) shareholders doesn't alleviate pain of one-year loss
It's nice to see the AbCellera Biologics Inc. ( NASDAQ:ABCL ) share price up 16% in a week. But that is minimal...
- Reuters
AbCellera to make C$701 million co-investment in Canada
Over the next eight years, the company will invest C$401 million in the project, and the governments of Canada and British Columbia will contribute C$225 million and C$75 million, respectively. The project is expected to create hundreds of new high-skilled jobs at AbCellera.
- Reuters
UPDATE 1-AbCellera to make C$701 million co-investment in Canada
AbCellera Biologics said on Wednesday it will make a C$701 million ($515.6 million) co-investment with the governments of Canada and British Columbia to strengthen capabilities for drug development, manufacturing and clinical research in the country. Over the next eight years, the company will invest C$401 million in the project, and the governments of Canada and British Columbia will contribute C$225 million and C$75 million, respectively.
TheStreet.comThese Small-Cap Biotech Stocks Have the Wind at Their Back
After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.
Business WireAbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
VANCOUVER, British Columbia, May 24, 2023--AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development. Over the next eight years, AbCellera plans to invest CA$401 million in the project, and the Governments of Canada and British Columbia will contrib
InvestorPlace7 Growth Stocks That Could Double Your Money in 2023
While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks. However, if the circumstances hit just right, these ideas can help get your portfolio on the right track quickly. According to ChatGPT, growth-oriented enterprises carry the expectation to grow at a faster rate than the overall market. Typically, we’re talking about 8% for the S&P 500 inde
- Simply Wall St.
AbCellera Biologics First Quarter 2023 Earnings: EPS Misses Expectations
AbCellera Biologics ( NASDAQ:ABCL ) First Quarter 2023 Results Key Financial Results Revenue: US$12.2m (down 96% from...
- Thomson Reuters StreetEvents
Q1 2023 Abcellera Biologics Inc Earnings Call
Q1 2023 Abcellera Biologics Inc Earnings Call
Motley FoolAbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL)Q1 2023 Earnings CallMay 04, 2023, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon and welcome to AbCellera first-quarter 2023 business update conference call.
ZacksAbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -16.67% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksAbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InvestorPlace7 Stocks Under $10 That Analysts Love
Generally speaking, you get what you pay for, which on paper doesn’t bode well for these bargain stocks under $10. Nevertheless, with thousands upon thousands of tradable securities available to public investors, at least a few will go unnoticed. That’s a shame for those missing out because some of these enterprises also command positive analyst ratings. Indeed, Wall Street’s top experts don’t just focus on blue chips with big price tags. Rather, cheap stocks to buy occasionally tickle the suits
Business WireAbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
VANCOUVER, British Columbia, April 17, 2023--AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
Motley Fool1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy
Artificial intelligence (AI) is hotter than ever thanks in large part to the intense interest sparked by OpenAI's ChatGPT. Interestingly, though, total private investment in AI decreased by nearly 27% in 2022, according to Stanford University's latest AI Index Report. The healthcare sector should provide a huge opportunity for investors in the years to come.
InvestorPlace7 Best Stocks Under $10 to Buy in April
Although financial advisors often direct you to established, reliable enterprises, in some cases, you can find compelling ideas among the best stocks under $10. To be fair, such companies tend to be more volatile than your standard blue-chip fare. On the other hand, should the masses catch on, these cheaply priced securities offer incredible upside potential. For willing speculators that can tolerate volatility, these stocks under $10 are particularly enticing because Wall Street analysts endors
Business WireAbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
VANCOUVER, British Columbia, April 11, 2023--AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
Business WireAbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
VANCOUVER, British Columbia, April 06, 2023--AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
InvestorPlace7 Thrilling Biotech Stocks for Aggressive Investors to Buy
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve’s possible response. If we’re being honest, circumstances don’t look particularly auspicious. Then again, the beauty of biotech stocks to buy is that
InvestorPlace7 Stocks to Bet On if You Want to Be Richer Than Elon Musk
If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you’re obviously going to need to conduct heavy research on the stocks that can make you rich. However, you also want to be smart about this. Just throwing your money at the cheapest and riskiest fare available will probably destroy your finances. Therefore, prospective investors who want to undertake this wild journey will need an effective balance. If it were me,
Business WireAbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
VANCOUVER, British Columbia & LONDON, March 22, 2023--AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
Business WireAbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
VANCOUVER, British Columbia, March 14, 2023--AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
- Simply Wall St.
Institutional investors may adopt severe steps after AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest 9.9% drop adds to a year losses
Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable...
Business WireAbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
VANCOUVER, British Columbia, February 23, 2023--AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
- Motley Fool
AbCellera Biologics (ABCL) Q4 2022 Earnings Call Transcript
Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL)Q4 2022 Earnings CallFeb 21, 2023, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon.